The number of potential competitors to AbbVie’s blockbuster product Humira (adalimumab) is growing after Boehringer Ingelheim received EU marketing authorization for its biosimilar version, Cytelzo, which is also the company’s first biosimilar to gain a European approval.
A total of four Humira biosimilars are now authorized in Europe: Amgen was first to secure approval with Amgevita and...






